Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Hatherill

Showing results (171-180 of 222) with videos related to

Pageof 23
Sort By:
Vaccine|June 7, 2015
The tuberculosis vaccine H4:IC31 is safe and induces a persistent polyfunctional CD4 T cell response in South African adults: A randomized controlled trialHennie Geldenhuys, Helen Mearns, David J C Miles, et al.
The Lancet. Global Health|October 18, 2025
Screening for asymptomatic tuberculosis among adults with household exposure to pulmonary tuberculosis: a prospective observational cohort studySimon C Mendelsohn, Humphrey Mulenga, Michele Tameris, et al.
ERJ Open Research|March 11, 2026
Optimisation and application of a T-cell antigen-specific activation assay as diagnostic and treatment-monitoring tool for tuberculosisMunyaradzi Musvosvi, Elisa Nemes, Michele Tameris, et al.
Chest|February 5, 2025
Trajectories of Interferon-Gamma Release Assay Results Over 2 Years in Independent Cohorts From China, South Africa, Tanzania, and the United StatesCheng Chen, Hao Xue, C Robert Horsburgh, et al.
The Lancet. Respiratory Medicine|August 17, 2019
Live-attenuated Mycobacterium tuberculosis vaccine MTBVAC versus BCG in adults and neonates: a randomised controlled, double-blind dose-escalation trialMichele Tameris, Helen Mearns, Adam Penn-Nicholson, et al.
Medrxiv : the Preprint Server for Health Sciences|February 20, 2025
Screening for Asymptomatic Tuberculosis among Adults with Household Exposure to a Patient with Pulmonary TuberculosisSimon C Mendelsohn, Humphrey Mulenga, Michele Tameris, et al.
European Respiratory Review : an Official Journal of the European Respiratory Society|June 8, 2022
End-point definition and trial design to advance tuberculosis vaccine developmentAlberto L Garcia-Basteiro, Richard G White, Dereck Tait, et al.
Plos Medicine|April 17, 2019
Discovery and validation of a prognostic proteomic signature for tuberculosis progression: A prospective cohort studyAdam Penn-Nicholson, Thomas Hraha, Ethan G Thompson, et al.
The Lancet. Microbe|July 4, 2024
Implications of subclinical tuberculosis for vaccine trial design and global effectGavin J Churchyard, Rein M G J Houben, Katherine Fielding, et al.
Plos Medicine|July 19, 2019
Correction: Discovery and validation of a prognostic proteomic signature for tuberculosis progression: A prospective cohort studyAdam Penn-Nicholson, Thomas Hraha, Ethan G Thompson, et al.
Pageof 23

Showing results (171-180 of 222) with videos related to

Sort By:
Pageof 23
Vaccine|June 7, 2015
The tuberculosis vaccine H4:IC31 is safe and induces a persistent polyfunctional CD4 T cell response in South African adults: A randomized controlled trialHennie Geldenhuys, Helen Mearns, David J C Miles, et al.
The Lancet. Global Health|October 18, 2025
Screening for asymptomatic tuberculosis among adults with household exposure to pulmonary tuberculosis: a prospective observational cohort studySimon C Mendelsohn, Humphrey Mulenga, Michele Tameris, et al.
ERJ Open Research|March 11, 2026
Optimisation and application of a T-cell antigen-specific activation assay as diagnostic and treatment-monitoring tool for tuberculosisMunyaradzi Musvosvi, Elisa Nemes, Michele Tameris, et al.
Chest|February 5, 2025
Trajectories of Interferon-Gamma Release Assay Results Over 2 Years in Independent Cohorts From China, South Africa, Tanzania, and the United StatesCheng Chen, Hao Xue, C Robert Horsburgh, et al.
The Lancet. Respiratory Medicine|August 17, 2019
Live-attenuated Mycobacterium tuberculosis vaccine MTBVAC versus BCG in adults and neonates: a randomised controlled, double-blind dose-escalation trialMichele Tameris, Helen Mearns, Adam Penn-Nicholson, et al.
Medrxiv : the Preprint Server for Health Sciences|February 20, 2025
Screening for Asymptomatic Tuberculosis among Adults with Household Exposure to a Patient with Pulmonary TuberculosisSimon C Mendelsohn, Humphrey Mulenga, Michele Tameris, et al.
European Respiratory Review : an Official Journal of the European Respiratory Society|June 8, 2022
End-point definition and trial design to advance tuberculosis vaccine developmentAlberto L Garcia-Basteiro, Richard G White, Dereck Tait, et al.
Plos Medicine|April 17, 2019
Discovery and validation of a prognostic proteomic signature for tuberculosis progression: A prospective cohort studyAdam Penn-Nicholson, Thomas Hraha, Ethan G Thompson, et al.
The Lancet. Microbe|July 4, 2024
Implications of subclinical tuberculosis for vaccine trial design and global effectGavin J Churchyard, Rein M G J Houben, Katherine Fielding, et al.
Plos Medicine|July 19, 2019
Correction: Discovery and validation of a prognostic proteomic signature for tuberculosis progression: A prospective cohort studyAdam Penn-Nicholson, Thomas Hraha, Ethan G Thompson, et al.
Pageof 23